Fosinopril is an inhibitor of angiotensin-converting enzyme (ACE) that exhibits antihypertensive and anti-atherosclerotic activities. Fosinopril is clinically used to treat congestive heart failure (CHF). In vivo, fosinopril decreases expression of toll-like receptor 4 (TLR 4) and NF-κB, suppressing formation of atherosclerotic plaques. Additionally, fosinopril decreases left ventricular hypertrophy, pressure, and expression of TGF-β1 in spontaneously hypertensive rats.
| Cas No. | 88889-14-9 |
|---|---|
| Purity | ≥98% |
| Formula | C30H45NNaO7P |
| Formula Wt. | 585.64 |
| IUPAC Name | sodium;(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate |
| Synonym | Dynacil; Eliten; Fosinil; Fosinopril sodium; Fosinorm; Fosipres; Fositen; Fositens; Foziretic; Fucithalmic; Hiperlex; Monopril; Newace; Sapril; Staril; Tenso Stop; Tensogard |
| Melting Point | 196-198°C |
| Appearance | White crystalline powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | F5773 Info Sheet PDF |
|---|
Yang S, Li R, Tang L, et al. TLR4-mediated anti-atherosclerosis mechanisms of angiotensin-converting enzyme inhibitor--fosinopril. Cell Immunol. 2013 Sep-Oct;285(1-2):38-41. PMID: 24044965.
Huang K, Dai G. The effect and mechanism of forsinopril on ventricular hypertrophy of SHR and left ventricular pressure overloading rat. J Huazhong Univ Sci Technolog Med Sci. 2002;22(1):17-20. PMID: 12658773.
